Anti-Inflammatory, Sleep, and Longevity

How this common plant flavonoid calms inflammation, promotes restful sleep via GABA pathways, and supports healthy aging by preserving NAD+

Apigenin is a pale-yellow flavonoid found in chamomile tea, parsley, celery, and many other common plants. It's quiet but remarkably active in the body — it binds to the same receptors targeted by anti-anxiety drugs, helps preserve NAD+ levels that decline with age, and suppresses the chronic inflammation that drives so many modern diseases [1][3][4]. You're probably already getting small amounts from a daily cup of chamomile tea; concentrated supplements are increasingly popular for sleep and longevity support.

How Apigenin Works

Apigenin belongs to the flavone subclass of flavonoids — plant pigments that evolved to protect plants from UV radiation, insects, and pathogens. In humans, these compounds interact with receptors and signaling pathways in ways that science has only recently begun to map in detail.

Calming the Nervous System: GABA Receptor Binding

The most well-characterized mechanism of apigenin is its interaction with GABA-A receptors, the same receptors targeted by benzodiazepine medications like Valium and Xanax. Apigenin acts as a partial agonist at the benzodiazepine binding site — it occupies the receptor and produces mild calming and sedative effects, but without the same potency or addiction risk as pharmaceutical benzodiazepines [1].

This is why chamomile tea has been used as a calming remedy for centuries, and why apigenin supplements are now commonly taken for:

Sleep onset: Reducing the time it takes to fall asleep by quieting the nervous system
Mild anxiety: Taking the edge off stress without cognitive impairment
Muscle relaxation: Reducing physical tension

A large cohort study in Italian adults found that higher dietary apigenin intake was independently associated with better sleep quality — one of the few polyphenols to show this association at the population level [5].

Preserving NAD+: The CD38 Connection

One of apigenin's most significant recently discovered roles involves NAD+ metabolism. NAD+ is a coenzyme essential for energy production, DNA repair, and sirtuin activity — proteins linked to longevity. As we age, NAD+ levels in tissues fall by roughly 50%, contributing to fatigue, metabolic dysfunction, and accelerated aging.

A major driver of this decline is an enzyme called CD38, which consumes NAD+ and becomes more active with age. Apigenin is one of the most potent natural inhibitors of CD38 identified to date [3]. In a landmark study by Escande et al. published in Diabetes, apigenin administration to obese mice nearly doubled liver NAD+ levels, reduced global protein acetylation (a marker of improved sirtuin function), and improved multiple aspects of glucose and lipid metabolism [3]. This mechanism is shared by the popular supplement quercetin and is part of why apigenin is sometimes paired with NAD+ precursors like NMN or NR in longevity protocols.

Anti-Inflammatory Action: NF-kB and Beyond

Chronic low-grade inflammation — sometimes called "inflammaging" — is increasingly recognized as a root driver of cardiovascular disease, metabolic syndrome, neurodegeneration, and cancer. Apigenin targets several key nodes of the inflammatory signaling cascade [4]:

NF-kB suppression: Blocks nuclear translocation of NF-kB, a master regulator of inflammatory gene expression
COX-2 inhibition: Reduces production of prostaglandins (similar mechanism to ibuprofen, but milder)
Cytokine reduction: Lowers IL-6, TNF-α, and IL-1β in cellular and animal studies
PI3K/Akt pathway modulation: Dampens inflammatory signaling at a cellular level

Cancer Prevention: Preclinical Evidence

Epidemiological data suggests that diets rich in flavones correlate with reduced risk of certain cancers, particularly breast, prostate, digestive tract, and skin cancers [2]. In laboratory and animal models, apigenin has demonstrated:

Induction of apoptosis (programmed cell death) in cancer cell lines
Cell-cycle arrest — stopping cancer cells from dividing
Anti-angiogenic effects — limiting blood vessel formation that feeds tumors
Suppression of metastasis — reducing cancer cell migration

Direct evidence from human clinical trials is limited, and apigenin should not be interpreted as a treatment for cancer. These findings reflect preclinical research, though the mechanistic plausibility is well-established.

Food Sources and Supplementation

Richest dietary sources of apigenin:

Chamomile tea (highest known source — dried chamomile flowers contain up to 1% apigenin by weight)
Fresh parsley (particularly flat-leaf)
Celery and celery seeds
Artichokes
Thyme and oregano
Chamomile, passionflower, and lemon balm teas

Supplement dosing: Most supplemental apigenin products range from 50–200 mg/day. Research in animal models has used doses equivalent to tens of milligrams per kilogram of body weight, so human doses in the 100–200 mg range are likely modest. There are no established clinical trial–derived optimal doses in humans as of yet.

Bioavailability note: Apigenin from chamomile occurs primarily as apigenin-7-glucoside (bound to sugar). Upon digestion, it's hydrolyzed to free apigenin in the gut. Absorption appears reasonable, though highly variable between individuals. Taking with food containing some fat may improve absorption.

Safety: Apigenin is generally well tolerated at typical supplemental doses. It may mildly enhance the effects of sedative medications (benzodiazepines, sleep aids) and should be used cautiously in that context. Due to its blood-thinning properties at higher doses, people on anticoagulants should consult a physician.

See our quercetin page for another well-studied flavonoid with overlapping mechanisms and complementary benefits.

Evidence Review

GABA Receptor Binding and Sedation: Foundational Study

The earliest rigorous characterization of apigenin's neurological mechanism was published by Viola et al. (PMID 7617761) in Planta Medica in 1995. The researchers isolated apigenin from Matricaria recutita (chamomile) and used radioligand displacement assays to demonstrate that apigenin competes for the benzodiazepine binding site on GABA-A receptors. Importantly, in behavioral studies in mice, apigenin produced mild sedative effects and reduced exploratory behavior consistent with anxiolytic activity, without the anticonvulsant or myorelaxant effects of full benzodiazepine agonists. This selectivity profile is more consistent with a partial agonist, which explains the gentler clinical effect observed compared to pharmaceutical benzodiazepines. This study established the mechanistic rationale for chamomile's traditional use as a calming herb and laid the groundwork for apigenin as a dietary source of mild GABA-ergic modulation.

Sleep Quality: Population Cohort Evidence

Godos et al. (PMID 32357534), published in Nutrients in 2020, analyzed dietary polyphenol intake and sleep quality in 1,936 adults in southern Italy using validated food frequency questionnaires and the Pittsburgh Sleep Quality Index. Among all flavonoids assessed, apigenin showed a statistically significant inverse association with poor sleep quality (OR 0.62, 95% CI: 0.43–0.88 for highest vs. lowest intake quartile), meaning those with higher dietary apigenin intake were significantly less likely to report inadequate sleep. The association was independent of confounders including age, sex, BMI, physical activity, and total energy intake. The study is observational, so causality cannot be established, but the specificity of the association to apigenin (rather than total flavonoid intake) adds biological plausibility given its known GABA-receptor activity.

NAD+ Preservation: The CD38 Inhibition Study

Escande et al. (PMID 23172919), published in Diabetes in 2013, performed comprehensive biochemical and animal model work establishing apigenin as a potent inhibitor of CD38 NADase activity. Key findings:

In purified enzyme assays, apigenin inhibited CD38 with an IC₅₀ in the nanomolar range
In cultured mouse embryonic fibroblasts, apigenin treatment elevated intracellular NAD+ levels and reduced global protein acetylation, suggesting increased sirtuin activity
Obese mice treated with apigenin showed significantly elevated liver NAD+ levels, with some tissues showing nearly a doubling of baseline concentrations
Metabolic outcomes in treated mice included improved insulin sensitivity, reduced triglycerides, and decreased hepatic lipid accumulation

The researchers included David A. Sinclair, a prominent longevity researcher at Harvard Medical School, among the authors. This study attracted significant attention in the aging research community and positioned apigenin alongside quercetin as a natural CD38 inhibitor worth investigating for NAD+ support. A limitation is that all metabolic experiments were performed in mice; human pharmacokinetics of apigenin differ and the effective concentrations may not be as easily achieved through supplementation.

Comprehensive Therapeutic Review

Salehi et al. (PMID 30875872), published in the International Journal of Molecular Sciences in 2019, conducted a broad review of in vivo apigenin research across disease models. Relevant findings include:

Diabetes models: Apigenin improved glucose homeostasis through AMPK activation and insulin-sensitizing effects in multiple rodent studies
Neurodegeneration: In Alzheimer's disease mouse models, apigenin reduced amyloid-beta accumulation and neuroinflammation; survival was extended in fly models of neurodegeneration
Mood and depression: Behavioral studies in mice showed reductions in immobility time (anti-depressant effect) and anhedonia reversal after apigenin administration
Cardiovascular protection: Endothelial protective effects, including reduced oxidative stress and improved nitric oxide bioavailability, were documented in multiple animal models

The authors note that while the preclinical evidence is extensive and mechanistically coherent, human clinical trial data remains limited, particularly for isolated apigenin supplementation vs. chamomile extract in clinical populations. Most human evidence comes from chamomile extract studies, where apigenin is one of multiple active constituents.

Cancer Prevention: Mechanistic and Epidemiological Data

Shukla and Gupta (PMID 20306120), published in Pharmaceutical Research in 2010, reviewed the evidence for apigenin as a chemopreventive agent. The review covers:

Epidemiological associations: Dietary flavone intake inversely associated with breast, digestive tract, skin, and prostate cancers in observational studies
Apoptosis induction: Multiple mechanisms, including activation of caspase-3 and -9, mitochondrial pathway activation, and suppression of anti-apoptotic proteins (Bcl-2, Bcl-xL) across multiple cancer cell lines
Anti-angiogenic effects: Inhibition of VEGF signaling, reducing tumor vascular formation
Prostate cancer models: Apigenin feeding (20–50 μg/mouse/day) in TRAMP mice reduced tumor volumes and abolished metastasis in a later study; effects correlated with NF-kB suppression

The authors explicitly acknowledge that no human clinical trials for cancer prevention with supplemental apigenin have been completed, and cautiously describe its potential as a "promising chemopreventive candidate" rather than an established intervention.

2024 Review: Sleep and Aging Synthesis

Kramer and Johnson (PMID 38476603), published in Frontiers in Nutrition in 2024, synthesized the now-substantial body of evidence connecting apigenin to both sleep and aging. The review emphasizes the bidirectionality: poor sleep accelerates aging, and many mechanisms by which apigenin supports longevity (NAD+ preservation, sirtuin activation, reduced oxidative stress) also improve sleep architecture. Key points:

Animal studies consistently show improved sleep duration and quality after apigenin supplementation
The CD38/NAD+ mechanism may explain why apigenin benefits both aging and sleep — sirtuin 1 activity influences circadian gene expression (CLOCK, BMAL1)
Apigenin extends lifespan in C. elegans and fly models of neurodegeneration
The authors call for randomized controlled trials in humans testing apigenin specifically (not chamomile extract) for sleep onset and quality outcomes

Overall Evidence Assessment

Apigenin has a well-established mechanistic profile and strong preclinical support across multiple disease areas. The GABA-receptor basis for its sedative effects is among the better-characterized mechanisms for any plant flavonoid. The CD38-inhibition/NAD+ preservation story is compelling and biologically coherent but still relies primarily on animal data for dosing guidance. Anti-inflammatory and cancer-preventive properties are extensively documented in cell and animal models. What is currently lacking is a robust body of human RCT evidence — most clinical data comes from chamomile extract trials where apigenin is one of several active compounds. This gap should widen in coming years given significant research interest. Current evidence supports dietary and moderate-dose supplemental use with a favorable safety profile; high-dose supplementation for therapeutic purposes should await further human trial data.

References

Apigenin, a component of Matricaria recutita flowers, is a central benzodiazepine receptors-ligand with anxiolytic effectsViola H, Wasowski C, Levi de Stein M, Wolfman C, Silveira R, Dajas F, Medina JH, Paladini AC. Planta Medica, 1995. PubMed 7617761 →
Apigenin: a promising molecule for cancer preventionShukla S, Gupta S. Pharmaceutical Research, 2010. PubMed 20306120 →
Flavonoid apigenin is an inhibitor of the NAD+ase CD38: implications for cellular NAD+ metabolism, protein acetylation, and treatment of metabolic syndromeEscande C, Nin V, Price NL, Capellini V, Gomes AP, Barbosa MT, O'Neil L, White TA, Sinclair DA, Chini EN. Diabetes, 2013. PubMed 23172919 →
The Therapeutic Potential of ApigeninSalehi B, Venditti A, Sharifi-Rad M, Kregiel D, Sharifi-Rad J, Durazzo A, Lucarini M, Santini A, Souto EB, Novellino E, Antolak H, Azzini E, Setzer WN, Martins N. International Journal of Molecular Sciences, 2019. PubMed 30875872 →
Specific Dietary (Poly)phenols Are Associated with Sleep Quality in a Cohort of Italian AdultsGodos J, Ferri R, Castellano S, Angelino D, Mena P, Del Rio D, Caraci F, Galvano F, Grosso G. Nutrients, 2020. PubMed 32357534 →
Apigenin: a natural molecule at the intersection of sleep and agingKramer DJ, Johnson AA. Frontiers in Nutrition, 2024. PubMed 38476603 →